SCHEMBL20934727

SCHEMBL20934727

Nc1ccc(C2=CCN(C3COC3)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC18A3 Q16572 3/20 0.40
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ DRD2 P14416 1/20 0.36
▸ DRD4 P21917 1/20 0.36
▸ DRD3 P35462 1/20 0.36
▸ QDPR P09417 1/20 0.35
▸ ATR Q13535 1/20 0.35
▸ PARP1 P09874 4/20 0.34
▸ ESRRB O95718 1/20 0.34
▸ ESR1 P03372 1/20 0.34
▸ ESRRG P62508 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16795078 0.84 SLC18A3 (0.40) SLC18A3KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL20919593 0.79 CYP1B1 (0.38) SLC18A3KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL14930370 0.77 BTK (0.35) SLC18A3QDPRATRPARP1
SCHEMBL16795094 0.76 LPL (0.42) SLC18A3
SCHEMBL14925547 0.74 SOS1 (0.38) SLC18A3ATRPARP1
SCHEMBL14811046 0.73 HTR6 (0.43) SLC18A3KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL31706770 0.71 ALDH1A1 (0.42) SLC18A3KDM4EALDH1A1MAPTATR
SCHEMBL20842182 0.70 SLC18A3 (0.47) SLC18A3QDPRPARP1ESRRBESR1
SCHEMBL24981840 0.70 CTSC (0.52) ATR
SCHEMBL22306951 0.69 SOS1 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019491-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF EMD Serono Research and Development Institute, Inc. 2023-01-19 — — US disclosed
WO-2019079373-A1 PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019491-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF DTYMK, TBKBP1, NFKBIA SLC18A3 4512/4885KDM4E 617/4885ALDH1A1 3953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback